- The trial data reports mild, mostly local side effects: itching, redness and irritation at the application site.
- No drug-related serious adverse events were reported in the Phase 3 trial at the doses tested.
- The safety picture is short term. The trials ran for months, not years, so long-term effects are unquantified.
- Pyrilutamide is a research compound, not a licensed medicine. Norwood Labs makes no safety or treatment claims.
The short answer
On the evidence that exists, pyrilutamide (KX-826) has a cleaner safety profile than almost anything else in its category. The clinical data reports mild, mostly local side effects and no drug-related serious adverse events at the doses tested. The honest qualification, and it is a big one, is that the evidence is short term, company-reported, and does not yet tell us anything about years of continuous use.
What the trials actually reported
Kintor Pharmaceutical reported that KX-826 hit its Phase 3 primary endpoint in a 666-patient, 24-week, vehicle-controlled trial in China, with no drug-related serious adverse events. The side effects that did appear were the ones you would expect from a topical: application-site itching, redness and irritation, at rates broadly comparable to the vehicle (the carrier solution itself, without the active). That last point matters. When the active arm and the placebo-vehicle arm show similar local irritation, a large share of what gets reported as a “side effect” is actually the ethanol carrier, not the molecule.
The earlier Phase 2 data told the same story: mild and local. The pattern across the programme is consistent. Pyrilutamide is a low-irritation, well-tolerated topical in the data we have, which is exactly why it earned the reputation it has in the research community.
Systemic effects: the question that matters
The reason pyrilutamide was designed as a topical is the same reason it matters here: the goal was local androgen receptor blockade with minimal systemic exposure. The available data suggests transdermal absorption is low, and the trial programme reported no meaningful rate of the systemic antiandrogen signature (sexual side effects, mood changes) that plagues oral antiandrogens. That is reassuring and consistent with the design.
The honest caveat is that no human data has established that systemic exposure is zero, and the trials measured months, not years. Long-term endocrine effects, if any, would not show up in a 24-week study. This is the same unquantified-variable point that applies to every topical antiandrogen, and it is not solved for pyrilutamide simply because the short-term picture is clean.
What the community reports
Long-term community users describe pyrilutamide as the gentler option in the category, with the most common observations being mild dryness or a brief shed in the early weeks, both of which are also seen with the licensed alternatives in the class. A minority report results plateauing around the six-month mark, which is an efficacy observation rather than a safety one. None of this is controlled data, but it is consistent with the trial picture rather than contradicting it.
Compared against the alternative
Against RU-58841, the other topical antiandrogen in common research use, pyrilutamide is the better-documented and better-tolerated option in the data. RU-58841 has never completed human trials at all, so its side effect picture is assembled from animal work and anecdote. That is not to say RU-58841 is dangerous, only that pyrilutamide is the one of the two with an actual human safety dataset behind it, and that dataset is mild. The fuller comparison is in RU-58841 vs Pyrilutamide.
Honest risk framing
The accurate summary: pyrilutamide is well tolerated in short-term human trials, with mild local side effects and no reported drug-related serious adverse events, and it is designed for low systemic exposure. What does not exist is long-term human safety data, because the compound has not been through the years-long, thousands-patient safety studies that a licensed medicine requires. That is the precise difference between “clean short-term data” and “proven long-term safety”, and it is why pyrilutamide remains a research compound sold as a reference material, not a treatment.